Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

299
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
299
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

437
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
437
Antihypertensive Drugs: Action of Diuretics01:16

Antihypertensive Drugs: Action of Diuretics

566
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
566
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

258
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
258
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

373
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
373
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

426
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
426

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Long-Term Blood Pressure Trends Following a Remote Hypertension Intervention: A Secondary Analysis of the Digital Care Transformation - Remotely Delivered Hypertension Management Program.

Hypertension (Dallas, Tex. : 1979)·2025
Same author

Continual Versus Occasional Blood Pressure (COOL-BP) in Remote Hypertension Management.

American journal of hypertension·2025
Same author

Validation of self-reported hypertension in young adults in the US-based Growing Up Today Study (GUTS).

PloS one·2024
Same author

Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE Clinical Trial Program.

Circulation·2023
Same author

Remote Cardiovascular Hypertension Program Enhanced Blood Pressure Control During the COVID-19 Pandemic.

Journal of the American Heart Association·2023
Same author

Innovative Remote Management Solutions for the Control of Hypertension.

Hypertension (Dallas, Tex. : 1979)·2023
Same journal

The origin of clinical left ventricular ejection fraction measurement.

Nature reviews. Cardiology·2026
Same journal

Inclusive cardiovascular care for sexual and gender minority populations.

Nature reviews. Cardiology·2026
Same journal

Modular cardiac microtissues for interrogating cell-type contributions.

Nature reviews. Cardiology·2026
Same journal

Sleep and exercise can limit clonal haematopoiesis clone expansion and reduce associated atherosclerosis.

Nature reviews. Cardiology·2026
Same journal

Epigenetic regulation in atherosclerosis and its therapeutic potential.

Nature reviews. Cardiology·2026
Same journal

Coronary artery calcium on chest CT scans: from incidental finding to mandatory reporting.

Nature reviews. Cardiology·2026
See all related articles

Related Experiment Video

Updated: May 7, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.0K

Renal denervation for hypertension.

Naomi D L Fisher1,2, Ajay J Kirtane3,4,5

  • 1Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Boston, MA, USA. nfisher@bwh.harvard.edu.

Nature Reviews. Cardiology
|January 1, 2025
PubMed
Summary
This summary is machine-generated.

Renal denervation (RDN) offers a new procedural therapy for hypertension, independent of medication adherence. Recent FDA approvals for RDN systems mark a significant advancement in treating diverse hypertension cases.

More Related Videos

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

4.6K
Novel Approach for Simultaneous Recording of Renal Sympathetic Nerve Activity and Blood Pressure with Intravenous Infusion in Conscious, Unrestrained Mice.
11:08

Novel Approach for Simultaneous Recording of Renal Sympathetic Nerve Activity and Blood Pressure with Intravenous Infusion in Conscious, Unrestrained Mice.

Published on: February 14, 2018

10.1K

Related Experiment Videos

Last Updated: May 7, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.0K
A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

4.6K
Novel Approach for Simultaneous Recording of Renal Sympathetic Nerve Activity and Blood Pressure with Intravenous Infusion in Conscious, Unrestrained Mice.
11:08

Novel Approach for Simultaneous Recording of Renal Sympathetic Nerve Activity and Blood Pressure with Intravenous Infusion in Conscious, Unrestrained Mice.

Published on: February 14, 2018

10.1K

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology
  • Nephrology

Background:

  • Hypertension prevalence is rising globally, with control rates declining despite numerous medical therapies.
  • Procedural interventions like renal denervation (RDN) offer an alternative to medication, bypassing adherence issues.
  • RDN has evolved significantly over two decades, with refined devices, techniques, and trial designs.

Purpose of the Study:

  • To review the current landscape of hypertension control and the evolution of renal denervation (RDN).
  • To summarize the evidence supporting the efficacy and safety of RDN for hypertension treatment.
  • To provide practical guidance on patient selection and implementation of RDN procedures.

Main Methods:

  • Review of early studies and randomized clinical trials on renal denervation (RDN).
  • Analysis of sham-controlled clinical trials demonstrating RDN efficacy and safety.
  • Examination of international statements and guidelines for RDN implementation.

Main Results:

  • Two distinct RDN systems (radiofrequency and ultrasound) received FDA approval in late 2023.
  • Clinical trials demonstrated the efficacy and safety of RDN across the spectrum of hypertension.
  • RDN is effective in patients with mild, moderate, and resistant hypertension, including those on minimal medication.

Conclusions:

  • Renal denervation (RDN) is an established interventional therapy for hypertension, supported by robust clinical evidence.
  • FDA approval signifies a major milestone, enabling wider application of RDN for diverse patient populations.
  • Successful RDN implementation requires a multidisciplinary hypertension team and shared decision-making with patients.